Home › Compare › SRTSF vs ABBV
SRTSF yields 2.26% · ABBV yields 3.06%● Live data
📍 SRTSF pulled ahead of the other in Year 4
Combined, SRTSF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SRTSF + ABBV for your $10,000?
Gr. Sarantis S.A., together with its subsidiaries, produces and trades in cosmetics, household products, and parapharmaceutical products. It operates through four segments: Mass Market Cosmetics, Household Products, Other Sales, and Private Label Products. The company provides personal care products, including baby care, baby wash, grooming, hair care, hair colorant, hair styling, hand wash, oral care, personal hygiene, shaving, skin care, and sun care products, as well as deodorants and fragrances; and home care products, such as dishwashing, drainer care, food packaging, insect control, and shoe care products, as well as bathroom cleaners, cleaning tools, septic tank activators, and garbage bags. It also offers health care products comprising food supplements, health and self-care products, and skin and sun care products; cosmetics, including candle, make up, treatment, and home and other fragrance products; and professional products, such as cleaning tools, detergents, and food and other packaging products. The company offers its products through hypermarkets, supermarkets, groceries, beauty shops, and pharmacies. It operates in Greece, Poland, Romania, Bulgaria, Serbia, the Czech Republic, Slovakia, Hungary, North Macedonia, Bosnia, Portugal, Ukraine, Russia, Cyprus, and France, as well as exports its products to approximately 50 countries in Europe, Asia, Africa, and Oceania. The company was founded in 1930 and is headquartered in Athens, Greece.
Full SRTSF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.